Announcement PDF Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity INVION LIMITED ABN 76 094 730 417 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director DR JAMES CAMPBELL Date of last notice 19 March 2018 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Change to direct and indirect holdings. Note: Provide details of the circumstances giving rise to the relevant interest. Indirect holdings are Fusion Biosciences Pty Ltd of which Dr Campbell is a director; and James A Campbell and Kelly F Windmill of which Dr Campbell is a beneficiary. Date of change 12 February 2019 Total No. of securities held prior to change 4,186,772 shares directly and indirectly held Class Unlisted Share Options Number acquired 20,443,211 Share options exercisable at $0.03 each on or before 12 February 2023 (IVXAT). Number disposed Nil. Value/Consideration Nil consideration. Share Options issued following Shareholder Approval at EGM held 30 January 2019. Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Total No. of securities held after change 4,186,772 shares directly and indirectly held. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 20,443,211 Share options exercisable at $0.03 each on or before 12 February 2023 (IVXAT). Share Options issued following Shareholder Approval at EGM held 30 January 2019. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract n/a Nature of interest n/a Name of registered holder (if issued securities) n/a Date of change n/a No. and class of securities to which n/a interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired n/a Interest disposed n/a Value/Consideration n/a Interest after change n/a Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed n/a above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade n/a to proceed during this period? If prior written clearance was provided, on what date was this n/a provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011